Back to News
Market Impact: 0.35
Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.
Source: 247wallst.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Mounjaro and Zepbound drove a blowout quarter for Lilly, but falling realized drug prices and one-time revenue boosts that are not expected to recur raise questions about the rally's durability. The article provides no figures for the quarter or the price declines.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead